SCHEMBL16057309

SCHEMBL16057309

CCCc1ccc(-c2ccn(C(=O)O)c(=O)c2C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 1/20 0.40
▸ PDE10A Q9Y233 1/20 0.39
▸ RARB P10826 8/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ MGLL Q99685 1/20 0.36
▸ PLK1 P53350 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ RARA P10276 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ MTOR P42345 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ S1PR4 O95977 1/20 0.34
▸ S1PR1 P21453 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16056895 0.92 RARB (0.48) RARBPLK1ALDH1A1MEN1RARA
SCHEMBL16058690 0.89 S1PR1 (0.40) ALDH1A1MAPTRAB9ASMN1; SMN2KDM4E
SCHEMBL16056806 0.83 LMNA (0.41) ALDH1A1MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL14975270 0.81 KDM4E (0.39) L3MBTL1ALDH1A1MEN1MAPTKMT2A
SCHEMBL16057334 0.80 L3MBTL1 (0.42) PDE10ARARBL3MBTL1PLK1MEN1
SCHEMBL16056988 0.77 RARB (0.40) RARBALDH1A1S1PR1S1PR5
SCHEMBL16058501 0.74 EGFR (0.52) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL16057273 0.73 CYP3A4 (0.41) L3MBTL1MAPTKMT2ANPC1RAB9A
SCHEMBL16056811 0.71 HPGD (0.50) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL25146615 0.70 MCL1 (0.52) MCL1PDE10APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 MCL1 2993/4885PDE10A 436/4885RARB 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback